This segment focuses on the research, development, and commercialization of innovative therapies for gastrointestinal (GI) disorders. The primary focus is on tenapanor, a first-in-class medicine for irritable bowel syndrome with constipation (IBS-C) and for controlling serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, or hyperphosphatemia. Research and development activities include clinical trials to evaluate the efficacy and safety of tenapanor. The company utilizes small molecule therapeutics and focuses on improving the quality of life for patients suffering from GI conditions. Market positioning is centered on addressing unmet medical needs in the GI space, with a competitive advantage in its novel mechanism of action. Future opportunities include expanding the indications for tenapanor and developing additional GI-focused therapies. Regulatory aspects involve obtaining FDA approval and navigating international regulatory pathways. Partnerships with Kyowa Kirin, Fosun Pharmaceutical, and Knight Therapeutics support commercialization in various territories.

This segment is dedicated to the development of medicines for cardiorenal diseases, specifically targeting conditions related to kidney and heart health. The primary focus is on RDX013, a potassium secretagogue, for the treatment of hyperkalemia, a serious condition affecting patients with kidney and/or heart disease. The company is also developing RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Research and development activities include preclinical studies and clinical trials to assess the safety and efficacy of these drug candidates. The segment leverages small molecule therapeutics to address unmet needs in cardiorenal health. The patient impact is significant, as these therapies aim to improve outcomes and quality of life for patients with chronic kidney disease and related complications. Market positioning involves targeting specific patient populations with high unmet needs. Future opportunities include expanding the cardiorenal pipeline and exploring new therapeutic approaches. Regulatory aspects involve obtaining necessary approvals for clinical trials and commercialization. The company may seek partnerships to accelerate development and commercialization efforts.